Trial Profile
Effects of Drospirenone-ethinylestradiol and/or NOMAC-valerate Estradiol on Cardiovascular Risk in Women With Polycystic Ovary Syndrome
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Drospirenone/ethinylestradiol (Primary) ; Estradiol/nomegestrol (Primary) ; Metformin
- Indications Polycystic ovary syndrome
- Focus Biomarker; Pharmacodynamics
- 25 May 2012 New trial record